Transcriptional control of triglyceride metabolism: Fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Auwerx, Johan ^a   Schoonjans, Kristina ^a   Fruchart, Jean Charles ^a   Staels, Bart ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apo C III; Fibrates; LPL; PPAR; Triglycerides

Indexed keywords

APOLIPOPROTEIN C; CELL NUCLEUS RECEPTOR; FIBRIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

CONFERENCE PAPER; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EID: 0029759110     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05854-6     Document Type: Conference Paper

References (59)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34.
2. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolemia. Atherosclerosis 1993;104:1.
3. Ginsberg HN, Le N-A, Goldberg IJ et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287.
4. Wang C-S, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384.
5. Windler E, Chao Y, Havel RJ. Regulation of hepatic uptake of triglyceride-rich lipoproteins in the rat. J Biol Chem 1980;255:8303.
6. Quarfordt SH, Michalopoulos G, Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 1982;257:14642.
7. Choi SY, Cooper AD. A comparison of the roles of the low-density lipoprotein (LDL) receptor and the LDL receptor-related proteinα2-macroglobulin receptor in chylomicron remnant removal in the mouse in vivo. J Biol Chem 1993;268:15804.
8. Malmendier CL, Lontie J-F, Delcroix C, Dubois DY, Magot T, De Roy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemicpatients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989;77:139.
9. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphism adjacent to human apoprotein A-I gene: relation to hypertriglyceridemia. Lancet 1983;i:444.
10. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein C-III haplotype protective against hypertriglyceridemiais specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993;90:4562.
11. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science 1990;249:790.
12. de Silva HV, Lauer SJ, Wang J, et al. Over expression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein. J Biol Chem 1994;269:2324.
13. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypertrigyleridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994;269:23 610.
14. Parra HJ, Arveiller D, Evans AE, et al. A case control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM study. Arteriosclerosis Thromb 1992;12:701.
15. Auwerx J, Leroy P, Schoonjans K. Lipoprotein lipase: recent contributions from molecular biology. Crit Rev Clin Lab Sci 1992;29:243.
16. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver, CR, Beaudet AL, Sly WS and Valle, D. (eds.). The Metabolic Basis of Inherited Disease, 6th Edn. New York: McGraw Hill, 1989;1165.
17. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD. Detection and characterisation of the heterozygote state for lipoproteinlipase deficiency. Atherosclerosis Thromb 1989;9:326.
18. Miesenbock G, Holzl B, Foger B, et al. Heterozygous lipoprotein lipase deficiency due to a mis-sense mutation as the cause ofimpaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest 1993;91:448.
19. Babirak SP, Brown BS, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arteriosclerosis Thromb 1992;12:1176.
20. Williams KJ, Petrie KA, Brocia RW, Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. J Clin Invest 1991;88:1300.
21. Reddy JK, Warren JR, Reddy MK, Lalwani MD. Hepatic and renal effects of peroxisomal proliferators: biological implications. Ann NY Acad Sci 1982;386:81.
22. van den Bosch H, Schutgens RBH, Wanders RJA, Tager JM. Biochemistry of peroxisomes. Ann Rev Biochem 1992;61:157.
23. Lock EA, Mitchell AM, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Ann Rev Pharmacol Toxicol 1989;29:145.
24. Sirtori CR, Franceschini G. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol Ther 1988;37:167.
25. Isseman I, Green S. Activation of a member of the steroid hormone receptor super-family by peroxisome proliferators. Nature 1990;347:645.
26. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879.
27. Gottlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate chimera of the clofibric acid activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992;89:4653.
28. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor super-family that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992;6:1634.
29. Sher T, Yi HF, McBride W, Gonzalez FJ. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993;32:5598.
30. Tontonez P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: tissue specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224.
31. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. Cloning of a new member of the peroxisome proliferator activated receptor gene family from mouse liver. J Biol Chem 1993;268:26817.
32. Aperlo C, Pognonec P, Saladin R, Auwerx J, Boulukos K. Cloning and characterization of the transcriptional activities of the hamster peroxisomal proliferator activated receptor, haPPARγ Gene 1995; 162: 297-302.
33. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory elements in the peroxisome proliferator responsive element enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 1991;175:866.
34. Tugswood JD, Isseman I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognises a response element in the 5′ flanking sequence of the rat acyl-CoA oxidase gene. EMBO J 1992;11:433.
35. Zhang B, Marcus SL, Sajjadi FG, et al. Identification of a peroxisome proliferator responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA 1992;89:7541.
36. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, Capone JP. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive element of the rat hydratase/ dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl Acad Sci USA 1993;90:5723.
37. Muerhoff AS, Griffin KJ, Johnson EF. The peroxisome proliferator activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid ω-hydroxylase, by clofibric acid. J Biol Chem 1992;267:19051.
38. Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D. Peroxisome proliferator activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA Synthase gene by fatty acids. J Biol Chem 1994;269:18767.
39. Schoonjans K, Watanabe M, Suzuki H, et al. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995; 270: 19269-19276.
40. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994;269:31 012.
41. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771.
42. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993;90:2160.
43. Staels B, Auwerx J. Perturbation of developmental gene expression in rat liver by fibric acid derivatives; lipoprotein lipase and α-fetoprotein as models. Development 1992;115:1035.
44. Tontonez P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor. Cell 1994;79:1147.
45. Staels B, Vu-Dac N, Kosykh V, et al. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl Co-enzyme A Oxidase. J Clin Invest, 1995; 95: 705-712.
46. Schoonjans K, Deeb S, Staels B, Auwerx J. The peroxisome proliferator activated receptor mediates the induction of lipoprotein lipase by fibrates. Submitted for publication.
47. Tolbert NE. Metabolic pathways in peroxisomes and glyoxysomes. Ann Rev Biochem 1981;50:133.
48. Auwerx J. Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for peroxisome proliferator activated receptors. Horm Res 1993;38:269.
49. Chatterjee B, Demyan WF, Lalwani ND, Reddy JK, Roy AK. Reversible alteration of hepatic messenger RNA species for peroxisomal and non-peroxisomal proteins induced by the hypolipidemic drug Wy 14643. Biochem J 1983;214:879.
50. Osumi T, Ozasa H, Hashimoto T. Molecular cloning of cDNA for rat acyl-CoA oxidase. J Biol Chem 1984;259:2031.
51. Reddy JK, Geol SK, Nemali MR, et al. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci USA 1986;83:1747.
52. Mietus-Snyder M, Sladek FM, Ginsburg GS, et al. Antagonism between apolipoprotein AI regulatory protein 1, EAR3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein C-III gene expression in liver and intestinal cells. Mol Cell Biol 1992;12:1708.
53. Ladias JAA, Hadzopoulou-Cladaras M, Kardassis D, et al. Transcriptional regulation of human apolipoprotein genes apo B, apo C-III, and apo A-II by members of the steroid hormone receptor super-family HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 1992;267:15 849.
54. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipidaemic subjects. Eur J ClinPharmacol 1983;23:56.
55. Rouffy J, Goy-Loeper J, Chanu B, Bakir R, Djian F. Comparative study of reduction in serum lipids obtained with benzafibrate and fenofibrate in twenty patients with type II hyperlipoproteinemia and low serum HDL. Sem Hop 1985;61:2115.
56. Sommariva D, Bonfiglioloi D, Pogliaghi I, Zanaboni L, Balboni E. Effects of procetrofen on serum lipids and lipoproteins and on post-heparin lipase activities in type II and type IV hyperlipoproteinemic patients. Curr Ther Res 1983;34:907.
57. Weisweiler P. Low-dose cholestipol plus fenofibrate: effects on plasma lipoproteins, lecithin: cholesterol acyl-transferase and postheparin lipases in familial hypercholesterolemia. Metabolism 1989;38:271.
58. Aalto-Setälä K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice. Diminished very-low-density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889.
59. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992;41:498.